An interventional study of Saliva swab testing in Candidates for Hereditary Pancreatic Cancer Testing, sponsored by Associazione Italiana per lo Studio del Pancreas. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-15.
Sponsored by Associazione Italiana per lo Studio del Pancreas · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies in Pancreatic Neoplasms with a site in Italy — 52 open to participants now, 76 under way, 11 of them phase 3. Pancreatic Neoplasms · Italy.
Among the 214 studies in Pancreatic Neoplasms with a site in Italy, this one has the largest planned enrollment of the 157 interventional ones that give a count, is one of 16 that started in 2022, is one of 43 with no phase, reaches primary completion later than 44 of the 75 other live ones, and was the 156th registered.
3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.
Browse Pancreatic Neoplasms studies →52 of the 214 studies in Pancreatic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Italy, United States, Belgium and 10 more countries
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18–99
Revolution Medicines, Inc. · Sites in Italy, United States, Austria and 2 more countries
Ages 18+
Alpha Tau Medical LTD. · Sites in Italy
Ages 18–120
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 64 · Phase 3 38 · Phase 4 2
First in 1997; this study’s year is marked. 16 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3,000 is above the median of 47 across 2,936 interventional studies indexed under Pancreatic Neoplasms.
Median enrollment 154 across the 157 interventional studies, 462 across the 55 observational. Of the 112 that completed or were terminated, 36 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
87 of 214 have an industry lead sponsor. The 10 most frequent:
Associazione Italiana per lo Studio del Pancreas is the lead sponsor of 5 studies on the registry; 4 are open to participants now.
Associazione Italiana per lo Studio del Pancreas has 1 study filed under Pancreatic Neoplasms — fewer than ten, so there is no comparison to draw.
18 of the studies in Pancreatic Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06071507IRCCS San RaffaeleManagement of Malignant Gastric Outlet Obstruction Between Surgery and Endoscopy | 2026-12 |
| NCT06069297IRCCS San RaffaelePrehabilitation in Pancreatic Surgery | 2026-12-16 |
| NCT02912949Partner Therapeutics, Inc.A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | 2026-12-31 |
| NCT07095621IRCCS San RaffaeleFeasibility and Effectiveness of Three-day Discharge After Distal Pancreatectomy | 2026-12-31 |
| NCT07241663Azienda Ospedaliera di PadovaSurgery for Locally Unresectable Pancreatic Cancer | 2026-12-31 |
Add all 18 to your calendar (.ics) → With an account.
Among the 214 studies in Pancreatic Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the PROPH-ITA Study is to perform genetic testing in family members of pancreatic cancer patients who may have a genetic predisposition. The subjects belong to the Italian Registry of Families At Risk of Pancreatic Cancer (IRFARPC, #NCT04095195). This investigational study will assess the genetic background of subjects with familiarity with pancreatic cancer only.
Participants may accept to undergo genetic testing as part of the IRFARPC registry, through a saliva-swab-based 41-gene panel test.
Up to 3,000 participants will be enrolled in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with familiarity with pancreatic cancer enrolled into the IRFARPC registry (NCT04095195) will be submitted to buccal swab for saliva-based genetic testing
Genetic: Saliva swab testing
41 pancreatic cancer predisposition genes will be tested through a saliva-based swab
Presence - absence of predisposing mutations
Prevalence of genetic mutations over the total tested
Time frame: 5 years
Correlation of genetic mutations with personal oncological history
Correlation between presence of predisposing mutation and prevalence of cancers
Time frame: 5 years
Correlation of genetic mutations with familial oncological history
Correlation between presence of predisposing mutation and prevalence of cancers in the family
Time frame: 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2022 (actual). Primary completion is estimated for Dec 2027, 60 months after the start.
Of 405 non-industry interventional studies with no phase under Pancreatic Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's planned 60 months is above that.
Counting every sponsor, half of 432 studies reached it within 44 months; a quarter within 26 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Associazione Italiana per lo Studio del Pancreas